Gilead Sciences, Inc. (GILD)'s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients  
11/15/2012 10:02:15 AM

GLASGOW, England--(BUSINESS WIRE)--Gilead Sciences (Nasdaq:GILD) today announced Phase 3b clinical trial results from STaR (Single Tablet Regimen), the first head-to-head study comparing the single tablet regimens Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) and Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) in treatment-naïve adults with HIV infection. Data demonstrated that Complera, which is marketed as Eviplera® in the European Union, is non-inferior to Atripla based on the proportion of patients with HIV RNA levels (viral load) < 50 copies/mL at 48 weeks.